DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Vinflunine
Vinflunine
MASCC/ESMO ANTIEMETIC GUIDELINE 2016 with Updates in 2019
Combining Paclitaxel and Lapatinib As Second-Line Treatment for Patients with Metastatic Transitional Cell Carcinoma: a Case Series
Transitional Cell Carcinoma: Options Beyond Nsaids Julie Marie Gillem, DVM, DACVIM (Oncology) Overview
Oxaliplatin, 5-Fluorouracil and Leucovorin (FOLFOX) As Second- Line Therapy for Patients with Advanced Urothelial Cancer
Safe Handling of Cytotoxic, Monoclonal Antibody & Hazardous Non-Cytotoxic Drugs
Guideline for the Management of Extravasation
Tumor Immunotherapy—The Potential of Epigenetic Drugs to Overcome Resistance
Safety and Effectiveness of Vinflunine in Patients with Metastatic
(MDT) Guidance for Managing Bladder Cancer
Comparator Report on Cancer in Europe 2019 −Disease Burden, Costs and Access to Medicines
Improving Chemotherapy in Advanced Urothelial Cancer: Real-World Data Studies and Prospective Clinical Trials
In Vitro and in Vivo Experimental Models As Tools to Investigate the Efficacy of Antineoplastic Drugs on Urinary Bladder Cancer
Modeling Delays in Chemotherapy Induced Hematological Toxicities
Clinical Study Protocol: Nucog I - Vingem
View Will Be Helpful As a Foundation to Development and Design of Novel Tubulin Inhibitors Targeting Colchicine Site
Page 1 of 32 Scores: 4/11/2013
METASTATIC UROTHELIAL CARCINOMA Systemic Second-Line Therapy: the Platinum-Refractory Setting
Vinflunine for the Treatment of Metastatic Transitional Cell Carcinoma: Recent Evidence from Clinical Trials and Observational Studies
Top View
HHS Public Access Author Manuscript
Immediate Management of an Extravasation
EAU Guidelines on Upper Urinary Tract Urothelial Carcinoma 2020
Policy for the Management of Extravasation
Javlor PSU-014 Highlighted PI
Javlor, INN: Vinflunine Ditartrate
Management of Extravasation of a Systemic Anti-Cancer Therapy Including Cytotoxic Agents
EMA/PDCO Summary Report on the Review of the List of Granted Class Waivers
Chemical Compatibility of Chemoclave™ and Chemolock™
Cancer of the Bladder, Ureter, and Renal Pelvis
EMETOGENICITY of CHEMOTHERAPY REGIMENS Version 2019
Emerging Cytotoxic Alkaloids in the Battle Against Cancer: Overview of Molecular Mechanisms
Australian Public Assessment Report for Vinflunine Ditartrate
GUIDELINE for MANAGEMENT of EXTRAVASATION Extravasation Is a Severe Complication in the Administration of Cytotoxic Chemotherapy
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting Agent Nicholas F
Eribulin Mesylate: Mechanism of Action of a Unique Microtubule-Targeting
Bcl-2 Down-Regulation and Tubulin Subtype Composition Are Involved in Resistance of Ovarian Cancer Cells to Vinflunine
What About « Triple Negative » Breast Cancer
Bladder Cancer
Guidelines on Treatment of Extravasation with Cytotoxic Drugs
Combined Treatment with Low Concentrations of Decitabine and SAHA Causes Cell Death in Leukemic Cell Lines but Not in Normal Peripheral Blood Lymphocytes
Chemotherapy for Recurrent Or Metastatic Breast Cancer
The First Slovak Experience with Second-Line Vinflunine in Advanced
Emetic Risk of Single Intravenous Antineoplastic Agents in Adults
Drug-Resistant Urothelial Cancer Cell Lines Display Diverse Sensitivity
Javlor, INN- Vinflunine
Vinflunine (Javlor) Monotherapy for Advanced Breast Cancer
Bladder Cancer
Low Doses of Decitabine Improve the Chemotherapy Efficacy Against
VINFLUNINE Regimen
761034Orig1s000
Chemotherapy Options Beyond the First Line in HER-Negative Metastatic Breast Cancer
New Treatment Paradigms for Optimizing Survival in Advanced
Protocol Template
Australian Public Assessment for Eribulin Mesilate
Availability of Evidence of Benefits on Overall Survival and Quality of Life Of
Stathmin Potentiates Vinflunine and Inhibits Paclitaxel Activity Soazig Malesinski, Philipp O
Guidance on the Safe Use of Neurotoxic Drugs (Including Vinca Alkaloids) in the Treatment of Cancer
Renal Impairment Hepatic Impairment Agent PK Summary Available
Medicine® OBSERVATIONAL STUDY
Novel Actions of the Antitumor Drugs Vinflunine and Vinorelbine on Microtubules1
NCCP Extravasation Classification of Systemic Anti-Cancer Therapy
Vinflunine for the Treatment of Advanced Or Metastatic
Pharmacy Medical Necessity Guidelines: Anti-Emetic Medications
TVCN Blank Document